Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Adaptin Bio Q3 2026 Results: Net Loss of $957K, Loss Narrows

Adaptin Bio, Inc. reported a net loss of $3.31 million for the nine months ended September 30, 2026, compared to a $3.80 million loss in the prior year period. The company remains in the development stage with no revenue, maintaining a stockholders' deficit of $1.67 million and a cash balance of $430,333 as of the reporting date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-1.0-1.7
Net income-1.0-1.7
EPS (diluted, $ a share)$-0.10$-0.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: APTN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Adaptin Bio, Inc.: key numbers

Shares outstanding
9.26MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.